Inflammatory Bowel Diseases
Conditions
Brief summary
Within this study, the investigators aim to directly compare the value of endoscopic remission, histologic remission and barrier healing for predicting long-term disease behavior in a large cohort of clinically remittent IBD patients.
Detailed description
Mucosal healing is a key therapeutic goal in the management of patients with inflammatory bowel diseases (IBD) that is associated with favorable long-term disease outcome. In addition, histologic remission is an emerging endpoint and first data suggest that functional assessment of the integrity of the intestinal barrier, i.e. barrier healing, by confocal laser endomicroscopy (CLE) correlates to clinical disease behavior and outcome. Within this study, the investigators will prospectively include IBD patients in clinical remission and assess endoscopic remission, histologic remission and barrier healing during baseline ileocolonoscopy. Participants will then be closely followed up in the IBD outpatient department of the University Hospital Erlangen every 4 to 8 weeks for participants under biological therapy and every 8 weeks for participants under conventional therapy. At each visit, clinical disease activity using the Mayo Clinical Score (MCS) and the Crohn's disease activity Index (CDAI), respectively, routine laboratory parameters and current and past medications will be recorded. Further, at each visit, major clinical events (MCE), defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded. The primary endpoint of this study is to comparatively assess the predictive values of barrier healing, endoscopic remission and histologic remission for predicting occurrence of MCE in IBD patients in clinical remission
Interventions
OTHERRecording of major clinical events
During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
Sponsors
University of Erlangen-Nürnberg Medical School
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Inclusion criteria
* patients with an established IBD diagnosis for at least 12 months duration * IBD patients in clinical remission
Exclusion criteria
* patients with poor bowel preparation * patients with total colectomy, * patients with concomitant beta blocker therapy, * patients with known allergy to fluorescein * patients with a planned change in IBD-related pharmacotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Predictive value of endoscopic remission in ulcerative colitis | 2 years | Endoscopic remission will be assessed using the Mayo Endoscopy Score in ulcerative colitis |
| Predictive value of endoscopic remission in Crohn's disease | 2 years | Endoscopic remission will be assessed using the simplified endoscopic index of severity (SES-CD) in Crohn's disease |
| Predictive value of histologic remission in ulcerative colitis | 2 years | Histologic remission will be assessed using the Robarts Histology Index and the Nancy Histology Index in ulcerative colitis |
| Predictive value of histologic remission in Crohn's disease | 2 years | Histologic remission will be assessed using a modified Riley Score in Crohn's disease |
| Predictive value of barrier healing | 2 years | Barrier healing will be assessed using the well-established Watson-Score as a semiquantitative grading system of the intestinal barrier function |
Countries
Germany
Contacts
Primary ContactTimo Rath, MD
Outcome results
None listed